meta|Evidence - COVID-19
click on circles to display study description...
chloroquine (n=18) vs. standard of care (n=12)
randomized controlled trial high risk of bias
chloroquine
chloroquine phosphate group: First dose of chloroquine phosphate 1 g first day, then 0.5g × 9 days
standard of care
according to the Chinese Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (5th Edition)
3 arms chloroquine, hydroxychloroquine and SoC
COVID 19 all comers
open-label
China, single center
Study planned to recruit 100 subjects with confirmed mild/moderate types ofCOVID-19. Study discontinuated after enrolling only 67 subjects with mild/moderate COVID-19Publication report only data on 48 patients with moderate type of COVID-19
chloroquine (n=10) vs. lopinavir/ritonavir (n=12)
randomized controlled trial some concerns about risk of bias
chloroquine 500 mg orally twice daily for 10 days
Lopinavir/Ritonavir 400/100 mg orally twice daily for 10 days
COVID 19 hospitalized
open label
China, Zhuhai
Fifth Affiliated Hospital of Sun Yat-sen University in Zhuhai
chloroquine (n=-9) vs. placebo (n=-9)
randomized controlled trial risk of bias NA
chloroquine
450 mg x2 day 1, then 450 mg/d for 4 days
placebo
COVID-19 mild to moderate
double-blind
1 center, Brazil
found in Axfors et al meta-analysis
powered by vis.js Network